Literature DB >> 11852061

Identification of functional VEGF receptors on human platelets.

Frode Selheim1, Holm Holmsen, Flemming S Vassbotn.   

Abstract

Platelets secrete platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) upon stimulation. We have demonstrated that platelets have functionally active PDGF alpha-receptors, a transmembrane tyrosine kinase involved in negative feedback regulation. Here we demonstrate the presence of the related VEGF receptors fms-like tyrosine kinase-1 and kinase-insert domain region on human platelets. VEGF itself did not cause platelet aggregation. However, addition of exogenous VEGF to SFRLLN or thrombin-stimulated platelets potentiated platelet aggregation. Moreover, thrombin-induced phosphoinositide 3-kinase and mitogen-activated protein kinase activity were enhanced in the presence of VEGF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11852061     DOI: 10.1016/s0014-5793(02)02232-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition.

Authors:  Rui Chen; Ge Jin; Wei Li; Thomas M McIntyre
Journal:  J Immunol       Date:  2018-08-27       Impact factor: 5.422

Review 2.  VEGF receptor signaling in vertebrate development.

Authors:  Joaquim Miguel Vieira; Christiana Ruhrberg; Quenten Schwarz
Journal:  Organogenesis       Date:  2010 Apr-Jun       Impact factor: 2.500

3.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.

Authors:  David K Jin; Koji Shido; Hans-Georg Kopp; Isabelle Petit; Sergey V Shmelkov; Lauren M Young; Andrea T Hooper; Hideki Amano; Scott T Avecilla; Beate Heissig; Koichi Hattori; Fan Zhang; Daniel J Hicklin; Yan Wu; Zhenping Zhu; Ashley Dunn; Hassan Salari; Zena Werb; Neil R Hackett; Ronald G Crystal; David Lyden; Shahin Rafii
Journal:  Nat Med       Date:  2006-04-30       Impact factor: 53.440

Review 4.  Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

Authors:  Maudy Walraven; Petronella O Witteveen; Martijn P J Lolkema; R van Hillegersberg; Emile E Voest; H M W Verheul
Journal:  Angiogenesis       Date:  2010-12-29       Impact factor: 9.596

5.  Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.

Authors:  Maudy Walraven; Marjolein Y V Homs; Astrid A M van der Veldt; Henk Dekker; Jose Koldenhof; Richard Honeywell; Arjan Barendrecht; Silvie A E Sebastian; Naomi Parr; Arnold C Koekman; Emile E Voest; Mark Roest; Suzanne J A Korporaal; Henk M W Verheul
Journal:  Angiogenesis       Date:  2018-03-12       Impact factor: 9.596

6.  Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: rare adverse effect of bevacizumab.

Authors:  Jeevan Kumar; Manorama Bhargava; Shyam Aggarwal
Journal:  Case Rep Oncol Med       Date:  2012-10-10

7.  Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.

Authors:  Samuel E DePrimo; Lily M Wong; Deepak B Khatry; Susan L Nicholas; William C Manning; Beverly D Smolich; Anne-Marie O'Farrell; Julie M Cherrington
Journal:  BMC Cancer       Date:  2003-02-07       Impact factor: 4.430

Review 8.  VEGF involvement in psoriasis.

Authors:  Mihaela Elena Marina; Iulia Ioana Roman; Anne-Marie Constantin; Carmen Mihaela Mihu; Alexandru Dumitru Tătaru
Journal:  Clujul Med       Date:  2015-07-01

Review 9.  Modulation of Immune Responses by Platelet-Derived ADAM10.

Authors:  Stefanie Maurer; Hans-Georg Kopp; Helmut R Salih; Korbinian N Kropp
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

10.  Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system.

Authors:  Shuai Bai; Tiantian Tian; Jose M Pacheco; Motoko Tachihara; Pingping Hu; Jiandong Zhang
Journal:  Transl Lung Cancer Res       Date:  2021-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.